September 24, 2025

BioLegacy Research Passes USDA Inspection with Zero Findings San Diego, CA - September 18, 2025 - BioLegacy Research, a leading contract research organization (CRO) specializing in preclinical services in regulated species (including rodents, dogs, minipigs, NHPs), is pleased to announce the successful completion of its recent USDA inspection, which concluded with zero findings. The inspection, conducted on September 2, 2025, reaffirms BioLegacy Research's ongoing commitment to the highest standards of quality, compliance, and animal welfare. The USDA's thorough review identified no concerns, underscoring the organization's dedication to operational excellence and regulatory integrity. For more information about BioLegacy Research and its...

July 21, 2025

PharmaLegacy Research LLC, dba. BTS Research Announces Expansion of their Headquarters & In Vitro Labs in their New San Diego Facility San Diego, CA We are excited to announce that BTS Research is now operating under a new name: BioLegacy Research  This new identity reflects our new leadership, expanded service platforms, and a renewed focus on innovation. We're positioned to better serve your preclinical research needs and help to bring your scientific breakthroughs to life. All existing agreements and relationships remain unchanged, and no action is required on your part. If you have any questions, please feel free to reach...

February 24, 2025

PharmaLegacy Research LLC, dba. BTS Research Announces Expansion of their Headquarters & In Vitro Labs in their New San Diego Facility San Diego, CA February 1, 2025 San Diego, California - BTS Research, a leading provider of in vitro and in vivo preclinical drug development services, announces the expansion of its San Diego operations. The move, from nearly 4,000 SF facility at 9990 Mesa Rim Road, Suite 100, to over 12,000 SF at 6042 Cornerstone Court West, Suite E, San Diego, CA 92121 represents a substantial increase in operational capacity to accommodate its growing operations following its recent acquisition by...

October 11, 2024

BTS Research Earns Full AAALAC Accreditation Renewal Continued Commitment to Excellence in Laboratory Animal Care San Diego, California - BTS Research a PharmaLegacy company is pleased to announce that the company has successfully renewed its FULL ACCREDITATION from the AAALAC International Council on Accreditation, recognizing its unwavering dedication to the highest standards in laboratory animal care and use. This prestigious accreditation underscores BTS Research's commitment to maintaining ethical and scientifically rigorous research practices. During the recent site visit, the AAALAC International Council commended BTS Research for its exemplary program and highlighted the following key areas: Leadership Involvement: The strong commitment...

September 15, 2024

BTS Research Successfully Completes USDA Inspection with Zero Findings San Diego, CA - August 28, 2024 - BTS Research, a leading contract research organization specializing in preclinical research services, is proud to announce the successful completion of its USDA inspection with zero findings. The inspection was triggered by the recent acquisition of BTS Research by PharmaLegacy, The inspection, which took place August 27, 2024, underscores BTS Research's commitment to maintaining the highest standards of quality and compliance in its operations. The USDA's thorough assessment found no areas of concern, reflecting BTS Research's dedication to excellence and regulatory adherence. Despite the...

August 29, 2024

PharmaLegacy acquires preclinical CRO BTS Research PharmaLegacy acquires preclinical CRO BTS Research, strengthening its preclinical services and expanding laboratory operations into North America PharmaLegacy Laboratories, a provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO). As a reputable CRO providing preclinical pharmacology services to clients worldwide, PharmaLegacy’s acquisition of BTS Research is an important step in its continuing growth. San Diego is a significant global R&D hub and the acquisition allows Pharmalegacy to join the greater communitywhile also strengthening and expanding PharmaLegacy’s global research capabilities and...

May 1, 2024

BTS Research Addresses FDA Warning Letter Satisfactorily From the desk of the President & CEO, April 1st, 2024 BTS is very pleased to have received a satisfactory completion of the findings the FDA had issued a warning letter on October 20th 2023. The findings were originally noted during their June 27th 2022 audit, which centered around tighter Study Director’s reviews and communications, more detailed inspection of records by the QAU and updating some equipment. This was in response to the FDA drug submission in Phase I. We are very pleased that we were able to address and close the warning letter...

February 23, 2024

BTS Research Completes Corrections of FDA 483 Observations From the desk of the President & CEO On July 8, 2022, U.S. Food and Drug Administration (FDA) Investigator concluded an inspection of the BTS Research facilities located in San Diego, CA and issued Inspectional Observations on the form FDA-483 that triggered a Warning Letter issued on Oct 20. 2023. The observations were mainly due to intermittent Study Director review of data, old equipment, and inspections frequency. BTS Research reported the completion of these observations on Nov 8th, 2023, to the FDA. These corrections triggered a more consistent Study Director review of...